Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01627002
Recruitment Status : Terminated
First Posted : June 25, 2012
Results First Posted : September 23, 2013
Last Update Posted : September 23, 2013
Sponsor:
Information provided by (Responsible Party):
ProtAffin Biotechnologie AG

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this study is to examine the safety, tolerability, immunogenicity and the way the body absorbs, distributes, breaks down and excretes various increasing single and multiple subcutaneous doses of PA401 in healthy subjects.

This study will also look at the effect of PA401 on inflammation in the lungs following an inhaled lipopolysaccharide (LPS) challenge (LPS is a bacterial cell wall fragment) and sputum induction (a procedure performed to help to cough up sputum (phlegm)) after a single subcutaneous dose of two dose levels.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Biological: PA401 Other: Placebo Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, FIH, Double-blind, Randomised Placebo-controlled Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of PA401, and the Effects of PA401 Following LPS Challenge, in Healthy Subjects
Study Start Date : May 2012
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PA401
PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
 Biological: PA401
Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
Placebo Comparator: Placebo
Placebo
 Other: Placebo
Subcutaneous


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Treatment Emergent Adverse Events [ Time Frame: up to 14 days post dose ]
  2. Immunogenicity [ Time Frame: Up to 28 days post dose ]
    Anti-drug antibody data

  3. Assessment of the Effect of PA401 on Induced Sputum Total Neutrophils [ Time Frame: 5.5 hours post dose ]
    Induced sputum was collected 6 hours after lipopolysaccharide challenge (5.5 hours following dosing) and assessed for neutrophils


Secondary Outcome Measures :
  1. Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Up to 12 time-points up to 48 hours post dose ]
  2. Pharmacokinetic Parameters: Time of Occurrence of the Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Up to 12 time-points up to 48 hours post dose ]
  3. Pharmacokinetic Parameters: Terminal Half-life (t1/2) [ Time Frame: Up to 12 time-points up to 48 hours post dose ]
  4. Pharmacokinetic Parameters: Area Under the Plasma Concentration-time Curve From Zero to Infinity [ Time Frame: Up to 12 time-points up to 48 hours post dose ]
  5. Assessment of the Effect of PA401 on Induced Sputum Percentage Neutrophils [ Time Frame: 5.5 hours post dose ]
    Induced sputum was collected 6 hours after lipopolysaccharide challenge (5.5 hours following dosing) and assessed for neutrophils


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult males aged 18 to 65 years

Exclusion Criteria:

  • Subjects with a clinically relevant medical history
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01627002


Locations
Layout table for location information
United Kingdom
Quintiles
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
ProtAffin Biotechnologie AG
Investigators
Layout table for investigator information
Principal Investigator: Jim Ritter, MD Quintiles, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: ProtAffin Biotechnologie AG
ClinicalTrials.gov Identifier: NCT01627002    
Other Study ID Numbers: PA401/01
2012-001189-14 ( EudraCT Number )
First Posted: June 25, 2012    Key Record Dates
Results First Posted: September 23, 2013
Last Update Posted: September 23, 2013
Last Verified: July 2013
Keywords provided by ProtAffin Biotechnologie AG:
Phase 1
First in Human
Healthy Volunteers
Lipopolysaccharide Challenge